Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen.

Online! Medical Crossfire®: An Oncologist's Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment

Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

This live Medical Crossfire®, presented at the 36th Annual Chemotherapy Foundation Symposium Meeting on Wednesday, November 7, 2018, discussed the importance of biosimilars in breast cancer as well as their relevance in other cancers that affect women’s health, such as gynecologic malignancies. This live Medical Crossfire®, which is also available for viewing online following the program, covers the state of the art in biosimilar development, with information on the specific tests used to verify biosimilar medications versus reference products, regulatory considerations, specific data from clinical trials of biosimilars in breast cancer, and strategies for assuring patients and other healthcare professionals of the rigorous testing of these agents for clinical use.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer with biosimilars are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the developmental and regulatory processes by which biosimilars are manufactured and approved by the FDA.
  • Evaluate efficacy, safety, and equivalence from clinical trials on biosimilars for breast cancer treatment.
  • Address barriers related to the integration of biosimilars into treatment of patients with breast cancer.
  • Increase awareness about emerging biosimilar agents currently in development for the treatment of breast cancer.

Faculty, Staff, and Planners' Disclosures


Bradley J. Monk
Bradley J. Monk, MD, FACS, FACOG
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis Oncology, Genmab, Gradalis, ImmunoGen, Incyte, Insys Therapeutics, Mateon Therapeutics, Merck, Myriad Genetics, Perthera, Pfizer, Precision Oncology, Roche/Genentech, Samumed, Takeda, Tesaro, Inc, VBL; Speakers Bureau: AstraZeneca, Clovis Oncology, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro, Inc.

Francisco J. Esteva
Francisco J. Esteva, MD, PhD
Professor of Medicine
Director, Breast Medical Oncology Program
Associate Director of Clinical Investigation
Laura & Isaac Perlmutter Cancer Center
NYU Langone Medical Center New York, NY

Disclosures: Grant Research Support: Novartis, Merrimack Pharmaceuticals, Kadmon, Pfizer; Consultant: Novartis, Genentech.

Kutluk Oktay
Kutluk Oktay MD, PhD
Professor of Obstetrics & Gynecology and Reproductive Sciences
Director, Laboratory of Molecular Reproduction and Fertility Preservation
Yale University School of Medicine
New Haven, CT

Disclosures: no relevant financial relationships with commercial interests.

Mark D. Pegram
Mark D. Pegram, MD
Director, Breast Cancer Oncology Program
Stanford Women’s Cancer Center
Co-director Stanford Molecular Therapeutic Program
Stanford, CA

Disclosures: Consultant: Pfizer, Amgen, Samsung Bioepis, and Roche/Genentech.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By